PHASE II STUDY OF ERLOTINIB AS A FIRST-LINE THERAPY FOR NON-SMALL-CELL LUNG CANCER PATIENTS ACCORDING TO THEIR CLINICAL PREDICTORS

被引：0
|
作者：
Lee, D. H. [1 ]
Kim, H. T. [2 ]
Kim, S. [1 ]
Suh, C. [1 ]
Lee, J. [1 ]
机构：
[1] Asan Med Ctr, Dept Internal Med, Div Oncol, Seoul, South Korea
[2] Natl Canc Ctr, Res Inst & Hosp, Ctr Lung Canc, Goyang, South Korea
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：103 / 103
页数：1
相关论文
共 50 条
  • [1] A phase II study of erlotinib as a first-line therapy for non-small-cell lung cancer patients with favorable clinical predictors and/or molecular predictors.
    Lee, Dae Ho
    Shin, Joo Hee
    Hong, Jeong-Sool
    Kim, Sang-We
    Suh, Cheolwon
    Kang, Yoon-Koo
    Lee, Jung Shin
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3457S - 3458S
  • [2] Erlotinib in First-line Therapy for Non-small Cell Lung Cancer: A Prospective Phase II Study
    Choi, Dae Ro
    Lee, Dae Ho
    Choi, Chang-Min
    Kim, Sang-We
    Suh, Cheolwon
    Lee, Jung-Shin
    ANTICANCER RESEARCH, 2011, 31 (10) : 3457 - 3462
  • [3] Erlotinib in the first-line treatment of non-small-cell lung cancer
    D'Arcangelo, Manolo
    Cappuzzo, Federico
    EXPERT REVIEW OF ANTICANCER THERAPY, 2013, 13 (05) : 523 - 533
  • [4] A Randomized, Phase II, Biomarker-Selected Study Comparing Erlotinib to Erlotinib Intercalated With Chemotherapy in First-Line Therapy for Advanced Non-Small-Cell Lung Cancer
    Hirsch, Fred R.
    Kabbinavar, Fairooz
    Eisen, Tim
    Martins, Renato
    Schnell, Fredrick M.
    Dziadziuszko, Rafal
    Richardson, Katherine
    Richardson, Frank
    Wacker, Bret
    Sternberg, David W.
    Rusk, Jason
    Franklin, Wilbur A.
    Varella-Garcia, Marileila
    Bunn, Paul A., Jr.
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (26) : 3567 - 3573
  • [5] Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy
    Coudert, B.
    Ciuleanu, T.
    Park, K.
    Wu, Y. -L.
    Giaccone, G.
    Brugger, W.
    Gopalakrishna, P.
    Cappuzzo, F.
    ANNALS OF ONCOLOGY, 2012, 23 (02) : 388 - 394
  • [6] First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging
    Dingemans, A. -M. C.
    de Langen, A. J.
    van den Boogaart, V.
    Marcus, J. T.
    Backes, W. H.
    Scholtens, H. T. G. M.
    van Tinteren, H.
    Hoekstra, O. S.
    Pruim, J.
    Brans, B.
    Thunnissen, F. B.
    Smit, E. F.
    Groen, H. J. M.
    ANNALS OF ONCOLOGY, 2011, 22 (03) : 559 - 566
  • [7] Clinical effect of erlotinib as first-line treatment for Asian elderly patients with advanced non-small-cell lung cancer
    Xin-Hua Xu
    Jin Su
    Xiang-Yang Fu
    Feng Xue
    Qiao Huang
    Dao-Jun Li
    Ming-Qian Lu
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 475 - 479
  • [8] Clinical effect of erlotinib as first-line treatment for Asian elderly patients with advanced non-small-cell lung cancer
    Xu, Xin-Hua
    Su, Jin
    Fu, Xiang-Yang
    Xue, Feng
    Huang, Qiao
    Li, Dao-Jun
    Lu, Ming-Qian
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (02) : 475 - 479
  • [9] FIRST-LINE ERLOTINIB IN ELDERLY PATIENTS (PTS) WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
    Merimsky, O.
    Cheng, A. C.
    Reck, M.
    Au, S. K.
    von Pawel, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 101 - 102
  • [10] A phase II study of erlotinib as first-line treatment of advanced non-small cell lung cancer.
    Giaccone, G
    Lechevalier, T
    Thatcher, N
    Smit, E
    Janmaat, M
    Rodriguez, J
    Oulid-Aissa, D
    Soria, JC
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 638S - 638S
12345